Search

Author/Creator Scheffold, Christian

1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Issue 33 (20th November 2021)

Authors:
Pal, Sumanta K.; McGregor, Bradley; Suárez, Cristina; Tsao, Che-Kai; Kelly, William; Vaishampayan, Ulka; Pagliaro, Lance; Maughan, Benjamin L.; Loriot, Yohann; Castellano, Daniel; Srinivas, Sandy; McKay, Rana R.; Dreicer, Robert; Hutson, Thomas; Dubey, Sarita; Werneke, Scott; Panneerselvam, Ashok...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 33(2021)
Page Start:
3725
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Issue 7 (July 2016)

Authors:
Choueiri, Toni K; Escudier, Bernard; Powles, Thomas; Tannir, Nizar M; Mainwaring, Paul N; Rini, Brian I; Hammers, Hans J; Donskov, Frede; Roth, Bruce J; Peltola, Katriina; Lee, Jae Lyun; Heng, Daniel Y C; Schmidinger, Manuela; Agarwal, Neeraj; Sternberg, Cora N; McDermott, David F; Aftab, Dana T;...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
917
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (May 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 94(2018)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. (9th August 2019)

Authors:
George, Daniel J.; Hessel, Colin; Halabi, Susan; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J.; Choueiri, Toni K.
Journal:
Oncologist
Issue:
Volume 24:Number 11(2019)
Page Start:
1497
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125]. (November 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 103(2018)
Page Start:
287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Issue 7 (July 2022)

Authors:
Motzer, Robert J; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M; Kessler, Elizabeth R; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Chris...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 7(2022)
Page Start:
888
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Issue 9 (20th March 2023)

Authors:
Yau, Thomas; Zagonel, Vittorina; Santoro, Armando; Acosta-Rivera, Mirelis; Choo, Su Pin; Matilla, Ana; He, Aiwu Ruth; Cubillo Gracian, Antonio; El-Khoueiry, Anthony B.; Sangro, Bruno; Eldawy, Tarek E.; Bruix, Jordi; Frassineti, Giovanni Luca; Vaccaro, Gina M.; Tschaika, Marina; Scheffold, Christi...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 9(2023)
Page Start:
1747
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. (December 2022)

Authors:
Apolo, Andrea B.; Powles, Thomas; Escudier, Bernard; Burotto, Mauricio; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Motzer, Robert J.; Choueiri, Toni K.
Journal:
European journal of cancer
Issue:
Volume 177(2022)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗